US drug giant Pfizer (NYSE: PFE) has moved closer to market with its biosimilar version of Roche’s (ROG: SIX) Avastin (bevacizumab).
Pfizer has announced positive top-line results from a study comparing its biosimilar, PF-06439535, to the original, which was the world’s second-best selling cancer drug last year with sales of nearly $7 billion.
At present, US biotech Amgen (Nasdaq: AMGN) and Ireland-incorporated drugmaker Allergan (NYSE: AGN) are furthest ahead with an Avastin biosimilar, having had their candidate, ABP 215, recommended for approval by a US Food and Drug Administration (FDA) committee this month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze